Published in final edited form as:

Ann Neurol. 2013 December ; 74(6): 826–836. doi:10.1002/ana.23908.

Comparing PET imaging and CSF measurements of A β

Susan M. Landau, PhD^{1,2}, Ming Lu, PhD³, Abhinav D. Joshi, PhD³, Michael Pontecorvo, PhD³, Mark A. Mintun, MD³, John Q. Trojanowski, MD, PhD⁴, Leslie M. Shaw, PhD⁴, and William J. Jagust, MD^{1,2,5} for the Alzheimer's Disease Neuroimaging Initiative

Susan M. Landau: slandau@berkeley.edu; Ming Lu: lu@avidrp.com; Abhinav D. Joshi: joshi@avidrp.com; Michael Pontecorvo: pontecorvo@avidrp.com; Mark A. Mintun: mintun@avidrp.com; John Q. Trojanowski: trojanow@mail.med.upenn.edu; Leslie M. Shaw: les.shaw@uphs.upenn.edu; William J. Jagust: jagust@berkeley.edu

¹Helen Wills Neuroscience Institute, University of California, Berkeley, CA

²Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA

³Avid Radiopharmaceuticals, Inc., Philadelphia, PA

⁴Department of Pathology and Lab Medicine, University of Pennsylvania, Philadelphia, PA

⁵School of Public Health, University of California, Berkeley, CA

Abstract

Objective—We examined agreement and disagreement between two biomarkers of A β deposition (amyloid PET and CSF A β_{1-42}) in normal aging and dementia in a large multicenter study.

Methods—Concurrently acquired florbetapir-PET and CSF A β were measured in cognitively normal, mild cognitive impairment (MCI), and Alzheimer's disease (AD) participants (N=374) from the Alzheimer's Disease Neuroimaging Initiative (ADNI). We also compared A β measurements in a separate group with serial CSF measurements over 3.1 $\pm$ 0.8 yrs that preceded a single florbetapir session. Additional biomarker and cognitive data allowed us to further examine profiles of discordant cases.

Results—Florbetapir and CSF A β were inversely correlated across all diagnostic groups, and dichotomous measurements were in agreement in 86% of subjects. Among subjects showing the most disagreement, the two discordant groups had different profiles: the florbetapir+/CSF A β – group was larger (N=13) and was made up of only normal and early MCI subjects; while the florbetapir–/CSF A β + group was smaller (N=7), had poorer cognitive function and higher CSF tau, but no ApoE4 carriers. In the longitudinal sample, we observed both stable longitudinal CSF

Correspondence to: Susan M. Landau, slandau@berkeley.edu, Tel: (510) 643-6616, Fax: (510) 642-3192, 118 Barker Hall MC #3190, UC Berkeley, Berkeley, CA 94720-3190.

*Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.ucla.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

SM Landau consults for Avid Radiopharmaceuticals, Inc., and has previously consulted for Synarc, Biogen Idec, and Janssen Alzheimer Immunotherapy

M Lu, AD Joshi, M Pontecorvo, and M Mintun are employees of Avid Radiopharmaceuticals, Inc.

L Shaw previously was consultant for Innogenetics and collaborates on quality assessment activities as part of the Alzheimer's Disease Neuroimaging Initiative.

JQ Trojanowski may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is co-inventor and he received revenue from the sale of Avid to Eli Lilly as co-inventor on imaging related patents submitted by the University of Pennsylvania.

W Jagust collaborates with Avid Radiopharmaceuticals, Inc. through participation in the Alzheimer's Disease Neuroimaging Initiative. W. Jagust has consulted in the past for GE Healthcare, and is currently a consultant to Genentech, Elan/Janssen Alzheimer Immunotherapy, Synarc, and TauRx.

A β trajectories and those actively transitioning from normal to abnormal, but the final CSF A β measurements were in good agreement with florbetapir cortical retention.

Interpretation—CSF and amyloid-PET measurements of A β were consistent in the majority of subjects in the cross-sectional and longitudinal populations. Based on our analysis of discordant subjects, the available evidence did not show that CSF A β regularly becomes abnormal prior to fibrillar A β accumulation early in the course of disease.

The beta-amyloid (A β) peptide is the primary component of neuritic plaques in Alzheimer's disease (AD) and can be quantified in humans using cerebrospinal fluid (CSF) and PET imaging measurements. A number of recent studies have reported that greater fibrillar A β in cortex, which has been measured previously with amyloid PET imaging using the tracer ¹¹C-Pittsburgh Compound B (PiB), is associated with low concentrations of CSF A β_{1-42} in normal aging and dementia¹⁻⁷. While this inverse relationship is consistent at the group level, there is not perfect agreement between the two markers, since some individuals with abnormal CSF A β_{1-42} have normal amyloid PET and vice versa³. Specifically, some studies have suggested that when there is a discrepancy, CSF A β_{1-42} may be more likely than amyloid PET to be abnormal in cognitively normal older individuals, leading to the possibility that CSF A β abnormalities precede fibrillar A β aggregation in cortex^{2, 8, 9}. However, conflicting findings have also been reported^{6, 10}, indicating that further research is needed to understand how often and under what circumstances discordance between the two A β markers occurs.

The goal of this study was to examine the agreement between A β markers in normal aging, MCI, and AD. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a large multisite study that includes a number of biomarkers including CSF and amyloid PET imaging with the ¹⁸F-labeled radioligand florbetapir. We evaluated two samples of ADNI participants: a large sample (N=374) with concurrent florbetapir and CSF measurements, and a separate smaller sample (N=60) with serial CSF measurements over approximately a 3 year period and ending prior to a single florbetapir scanning session. Based on previous studies, we expected to find evidence that abnormal A β can be detected in CSF prior to amyloid PET imaging, particularly in individuals with minimal or no cognitive deficits. We further predicted that other CSF, neuroimaging, genetic, and cognitive data in discordant cases would provide additional support for potentially differing roles of A β markers at different stages of disease severity.

Methods

ADNI

Our study samples were drawn from different phases of the Alzheimer's Disease Neuroimaging Initiative, a longitudinal multisite study supported by the NIH, private pharmaceutical companies, and nonprofit organizations with approximately 50 medical center and university sites across the United States and Canada (www.loni.ucla.edu/ADNI). Subjects in this report are ADNI participants with either cross-sectional CSF and florbetapir measurements, or longitudinal CSF measures with a single florbetapir timepoint.

Full inclusion/exclusion criteria are described in detail at www.adni-info.org. Briefly, all subjects were between ages 55 and 90 years, had completed at least 6 years of education, were fluent in Spanish or English, and were free of any other significant neurologic diseases. Participants with MCI, now referred to as late MCI (LMCI) had a subjective memory complaint, a Clinical Dementia Rating (CDR) of 0.5, and were classified as single- or multi-domain amnesic¹¹. An early MCI group (EMCI) differed from LMCI only based on education-adjusted scores for the delayed paragraph recall subscore on the WMS-R Logical

Memory II such that EMCI subjects were intermediate to normals and LMCI. Normal subjects had CDR scores of 0, and patients with AD met standard diagnostic criteria¹².

Participants

Our cross-sectional sample was made up of 374 subjects (103 Normal, 187 Early MCI, 62 Late MCI, 22 AD at the time of the florbetapir scan; see Table 1) who each had a single lumbar puncture (LP) and a florbetapir session between May 2010 and March 2012. LPs and florbetapir scans occurred within 2 weeks of each other (see Table 1).

Our longitudinal sample was made up of the 60 ADNI subjects (29 Normal, 31 MCI at enrollment) who underwent an average of 3.5 LPs (min = 2, max = 5) at approximately yearly intervals between October 2005 and November 2010, and subsequently underwent florbetapir scanning an average of 1.4 $\pm$ 0.6 yrs after the last LP. The majority of subjects had concurrent structural MRI and FDG scans, CSF tau and p-tau measurements, and cognitive function (e.g. mini-mental state examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)).

Over the approximately 5 year followup period, 5/29 (17%) of Normal subjects converted to MCI, while 16/31 (52%) of MCI subjects converted to AD and 3/31 (10%) of MCI subjects reverted to Normal (see Table 4).

All participants gave written informed consent that was approved by the Internal Review Board (IRB) of each participating institution.

Florbetapir Imaging and Analysis

Florbetapir image data were acquired from a variety of PET scanners and sites nationwide. Data preprocessing information is available online (adni.loni.ucla.edu/about-data-samples/image-data/). Briefly, image data was acquired in four 5 min frames 50–70 minutes after injection of approximately 10 mCi, the four frames were coregistered to one another, averaged, interpolated to a uniform image and voxel size (160 $\times$ 106 $\times$ 96, 1.5mm³), and smoothed to a uniform resolution (8mm FWHM) to account for differences between scanners¹³.

In order to quantify cortical A β , preprocessed florbetapir image data and coregistered structural magnetic resonance images (MRI) were analyzed using Freesurfer v4.5.0 (surfer.nmr.mgh.harvard.edu/) as described elsewhere^{14, 15} and online (adni.loni.ucla.edu/research/pet-post-processing/). We used one or, in most cases, two T1 structural 1.5 T or 3T MRI scans that were acquired as close as possible to the florbetapir scan to define cortical regions of interest that were averaged together, coregistered to the florbetapir images to extract mean cortical retention and then normalized to a cerebellar reference region as a summary measure of florbetapir retention for each subject.

CSF Data Analysis

LPs were carried out at ADNI sites as described in the online ADNI protocol (<http://adni.loni.ucla.edu/research/protocols/biospecimens-protocols/>). The CSF A β ₁₋₄₂, total tau (t-tau), and tau phosphorylated at threonine 181 (p-tau_{181p}) were measured using the multiplex xMAP Luminex platform with Innogenetics immunoassay kit-based reagent as described and validated previously¹⁶⁻¹⁸. Additional analysis details and quality control procedures appear online (<http://adni.loni.ucla.edu/>).

All longitudinal and cross-sectional CSF aliquots were anchored to the same baseline assay in order to use the cutoff values for abnormal and normal A β ₁₋₄₂, t-tau, and p-tau_{181p} status

that were established and validated for that assay¹⁷; details are provided in Supplementary Materials.

Additional biomarkers and cognitive tests

Information about measurement of additional biomarkers (ApoE4, hippocampal volume, FDG-PET) and neuropsychological testing appears in the Supplementary Materials.

Biomarker cutoffs

Subjects were categorized as abnormal (+) or normal (–) on florbetapir using a cortical retention ratio cutoff value of 1.11¹⁵. This value is based on the upper limit of the 95% confidence interval for the distribution of florbetapir values for young healthy controls¹⁹ and is consistent with a separate autopsy-validated sample²⁰. The CSF cutoffs from the autopsy-validated baseline assay used in this study were A β ₁₋₄₂=192 pg/mL, t-tau=93 pg/mL, and p-tau_{181p}=23 pg/mL¹⁷; low A β ₁₋₄₂ and high tau values were abnormal (+). Finally, to categorize subjects as abnormal (+) and normal (–) on FDG, we used a cutoff of 1.21 that was derived from an ROC analysis of normal and AD subjects in a separate ADNI population²¹.

Statistical Methods

All statistical tests were performed with SPSS v19.0 and carried out at $\alpha = 0.05$. Associations that included continuous CSF and florbetapir measurements were assessed using Spearman rank correlation coefficients (ρ) in order to account for the non-normally distributed nature of these amyloid measurements. Associations between ApoE4 carrier status and other dichotomous measurements were assessed with chi-square (χ^2) tests. The kappa (κ) statistic was used to quantify agreement between dichotomous (+/–) measurements (CSF, florbetapir, FDG) relative to what would be expected by chance.

Results

Descriptive information and biomarker associations in the cross-sectional population

Demographic information for the 374 normal, EMCI, LMCI, and AD participants in the cross-sectional sample is summarized in Table 1. Age, education, and sex were similar across diagnostic groups, while MMSE and ADAS-cog performance declined across groups as diagnostic severity increased. The percent of ApoE4 allele carriers and the percent of subjects categorized as abnormal (+) on each biomarker (florbetapir, CSF A β ₁₋₄₂, t-tau, and p-tau_{181p}, and FDG) also increased with diagnostic severity. Of these markers, FDG status was most consistent with diagnosis, with 17% of normals and 100% of AD patients categorized as abnormal.

Across all individuals, age was associated with continuous forms of biomarkers (florbetapir, CSF A β , t-tau, and p-tau, hippocampal volume, and FDG) while education was weakly correlated with FDG ($p=0.04$) not CSF t-tau, p-tau, A β ₁₋₄₂, hippocampal volume, or age.

Cross-sectional associations between CSF A β and florbetapir

The inverse relationship between continuous forms of concurrent CSF A β and florbetapir measurements for all diagnostic groups is plotted in Figure 1a, as well as cutoffs for abnormal and normal status (+/–) for each biomarker.

Using continuous measures, florbetapir was more closely correlated with CSF A β ($\rho = -0.74$) than with t-tau ($\rho = 0.51$) or p-tau ($\rho = 0.55$) across the entire sample. Similarly, within individual diagnostic groups, florbetapir associations were stronger with CSF A β (Normal, ρ

$= -0.67$; EMCI, $\rho = -0.72$; LCMI $\rho = -0.61$; AD, $\rho = -0.41$) than with t-tau (Normal, $\rho = 0.23$; EMCI, $\rho = 0.55$; LCMI $\rho = 0.57$; AD, $\rho = 0.17$) or p-tau (Normal, $\rho = 0.28$; EMCI, $\rho = 0.60$; LCMI $\rho = 0.55$; AD, $\rho = 0.30$).

We also evaluated dichotomous forms of these biomarkers. The majority (62%) of normals were negative for both florbetapir and CSF A β and the majority of AD patients (77%) were positive for both (Figure 1c). The proportion of subjects with agreement was stable across diagnostic groups (83–91%) and $\kappa = 0.72$ overall (Table 2).

Agreement between florbetapir status (+/–) and status on other biomarkers (CSF t-tau and p-tau, FDG) was moderate (CSF t-tau, $\kappa = 0.42$; CSF p-tau, $\kappa = 0.52$; FDG, $\kappa = 0.26$ for the total sample) but this was variable across diagnostic groups (Table 2; also see Supplementary Figure).

The proportion of ApoE4 carriers was highest for subjects who were positive for both markers, lowest for subjects negative for both, and intermediate for the 2 discordant groups (Figure 1d).

CSF A β and florbetapir disagreement

Across all diagnostic groups, 9–17% of subjects (52 subjects total; 31 florbetapir+/CSF A β –, 21 florbetapir–/CSF A β +) were discordant (Figure 1c).

Visual inspection of florbetapir–/CSF A β indicated that the quantitative florbetapir estimates plotted in the figure are consistent with qualitative interpretation (Figure 1b).

To identify subjects who were considerably discordant, as opposed to those with one or both A β measurements close to the cutoffs, we created $\pm 5\%$ confidence intervals around each cutoff (Figure 2). Out of the original 52 discordant subjects, 20 discordant subjects remained (13 florbetapir+/CSF A β – and 7 florbetapir–/CSF A β +). The diagnoses, cognitive measurements, and imaging and fluid biomarker profiles of these remaining discordant subjects are listed in Table 3. 100% (13/13) subjects in the florbetapir+/CSF A β – group were in the two most cognitively intact groups (cognitively normal or early MCI). The florbetapir–/CSF A β + group, on the other hand, had more cognitive impairment (5/7 subjects had a diagnosis of LMCI and AD) and higher CSF tau ($p = 0.01$) than the other discordant group, but a lower proportion of ApoE4 carriers (0/7 subjects, compared with 6/13 (46%) in the florbetapir+/CSF A β – group; Chi-square test; $p = 0.03$). Group differences between the other biomarkers were not significant ($p > 0.10$).

Longitudinal CSF A β trajectories for florbetapir +/- individuals

Demographic information for the longitudinally followed subjects is shown in Table 4. A number of subjects had changes in diagnosis during followup: 52% of MCI subjects converted to AD and 17% of normal individuals progressed to MCI prior to the florbetapir scan.

CSF A β trajectories for the longitudinally-followed, separate sample are plotted in Figure 3a. Subjects are divided by florbetapir status and by diagnosis at the time of florbetapir (end of CSF followup) so all AD subjects in Figure 3a were diagnosed as MCI at enrollment, and several Normal and MCI subjects had a different diagnosis at enrollment as well (see Table 4). Unlike the cross-sectional population, the CSF A β measures occurred more than a year before florbetapir scans. Nonetheless, kappa values reflecting agreement between the last CSF A β +/- status and florbetapir +/- status were similar to the cross-sectional dataset (Normal, $\kappa = 0.67$; MCI, $\kappa = 0.65$; AD, $\kappa = 0.82$). There were fluctuations in CSF A β over the course of followup for many subjects, but florbetapir+ individuals (top panel, Figure 3a) had

primarily downward CSF A β trajectories. Four subjects had normal CSF A β at enrollment and declines throughout the six-year followup, ending with abnormal -- or near abnormal -- measurements that preceded abnormal florbetapir status. While the gap between the last CSF measurement and the florbetapir scan leaves some uncertainty, the direction of change for these actively transitioning subjects suggests good agreement between coinciding CSF A β and florbetapir.

There were, however, several discordant subjects whose florbetapir scans appear in Figure 3 b–d (see Supplementary Materials for additional demographic and biomarker characteristics).

Discussion

We found that CSF A β_{1-42} and amyloid PET imaging measurements were inversely associated in the majority of subjects, and that dichotomous classification was in substantial agreement. There was no evidence from cross-sectional or longitudinal analyses that abnormal CSF A β precedes abnormal florbetapir early in the course of disease.

We observed good agreement between CSF A β and amyloid PET measurements across several comparisons: with continuous or dichotomous forms of the variables, using cross-sectional and longitudinal CSF measurements, and across diagnostic groups. Overall, the association between CSF A β and florbetapir explains approximately 55% of the variance in these measurements, which is comparable to previous studies with PiB²⁻⁷. As expected, the proportion of subjects who were abnormal on both markers increased with severity of diagnosis, but the overall proportions of subjects who had concordant (both normal or both abnormal) and discordant A β measurements was stable across diagnostic groups (83–91% concordant, 9–17% discordant). In the longitudinal CSF sample, there was considerable change in CSF A β from the beginning to end of the followup period for some subjects, with most change occurring in a decreasing direction. Consistent with the cross-sectional sample, there was good agreement between the final CSF A β and the subsequent florbetapir measurement.

Our data did not support the hypothesis that a decline in CSF A β precedes aggregation of fibrillar A β ^{2, 8}. In fact, among discordant subjects whose measurements were not close to the cutoffs, normal and EMCI subjects made up 100% of the CSF A β –/florbetapir+ group but only 29% of the CSF A β + /florbetapir– group (Figure 2). Because active accumulation of amyloid is most likely to occur prior to the onset of significant cognitive decline^{22, 23}, our findings support the possibility that fibrillar A β can be detected first in some individuals, which has been reported^{6, 10}, or that there is a complex relationship between different species of A β and the progression of disease. For example, although decreasing CSF A β measurements in AD are generally thought to reflect the accumulation of soluble forms of A β in neuritic plaques^{24, 25}, this process may be altered by comorbid pathology or other etiologies that influence the production or clearance of different A β species. Specifically, low CSF A β in the absence of neuritic plaques has been reported in other disorders such as amyotrophic lateral sclerosis and Creutzfeldt-Jacob syndrome²⁶. Detection may play an important role as well; a recent case study reported low CSF A β in the presence of diffuse plaques detected at autopsy but not with PiB-PET imaging²⁷. Although more longitudinal studies are needed, the existing evidence suggests that there may be considerable variability in the temporal dynamics and pattern of soluble and fibrillar A β .

Nonetheless, the combination of florbetapir and CSF marker information provided useful insight into diagnostic status for some subjects. For example, 3/22 subjects in the cross-sectional sample were diagnosed with AD at enrollment but were negative for both markers,

indicating that their dementia is likely due to non-AD pathology. Similarly, in the longitudinal sample, 4/31 MCI subjects converted to AD during the followup period but were negative for both markers (Figure 3a; one was borderline positive for CSF A β). Misdiagnosis in AD patients with normal CSF A β and amyloid PET has been suggested previously²⁸ and may account for some amyloid negative AD subjects in this study. Furthermore, comorbidities may have influenced the accuracy of the biomarker cutoffs themselves, and may account for inaccuracies in both clinical diagnoses and biomarker classifications. Of subjects who have come to autopsy, 5/9 ADNI MCI and AD subjects (not in this study) had comorbid pathologies such as alpha-synuclein pathology and tauopathy²⁹. Furthermore, in a recent study of dementia patients that included individuals with comorbidities, the sensitivity and specificity of CSF biomarker measurements was lower for clinical compared with neuropathological diagnosis³⁰, providing additional evidence that both misdiagnosis and non-AD pathology influence biomarker accuracy.

The longitudinal sample provided additional insight into the relationship between the two markers and the time course of the accumulation of amyloid pathology. While minimal longitudinal change in serial CSF A β measurements in normal or AD individuals has been reported previously^{1, 31}, we observed a combination of stable trajectories and considerable variability and declines for some individuals. CSF A β trajectories were variable over time for those who were florbetapir negative at the end of followup, but there was minimal net change. Among those who were ultimately florbetapir positive, we observed several individuals whose CSF A β actively declined throughout the 5 to 6 year followup period to levels that were abnormal or close to abnormal, and this status was ultimately reflected by their abnormal florbetapir scan as well. We note that there is ambiguity about whether CSF A β became abnormal before florbetapir or vice versa due to the approximately one year delay between the final CSF measurement and the florbetapir scan; however, the downward trajectory of CSF measurement appears to be informative.

Older age in our sample may account for why we did not find evidence that CSF A β becomes abnormal prior to amyloid PET measurements. Previous cross-sectional PiB studies suggesting a possible offset in the time course of A β abnormality had subjects as young as 43 (and a mean age in the mid 60s)^{2, 8}. Studies that did not report a pattern that was consistent with CSF A β becoming abnormal prior to amyloid PET had mean ages of approximately 65¹⁰ and 71⁶, while the subjects in the current study had a mean age of 73. Since A β aggregation may begin earlier than 50 years of age³², our subjects may have passed a critical time period where the offset would be most clearly observed. Older age in our population may also explain why we did not find any evidence for an initial increase in CSF A β followed by a subsequent decline, although to our knowledge this has only been reported in autosomal dominant AD^{22, 33} and not in late-onset AD³⁴.

Several other methodological factors may have contributed to our findings. Although we had a large sample overall, the relatively small numbers of discordant subjects (particularly in the longitudinal sample) made it difficult to draw conclusions about the cause of the discordance. Disagreement between CSF A β and florbetapir measurements may have been due to measurement problems such as errors introduced by PET image processing, the use of cutoffs with differing sensitivities and specificities, and standardizing CSF assays to the same set of cutoffs. Establishing standardization across laboratories for LP collection and CSF assay analysis is a significant challenge that is currently being addressed^{18, 35}. In addition, the cutoffs and distributions CSF A β and florbetapir differ in a way that influences the shape and linearity of their association. Both markers have an approximately bimodal distribution across the entire sample, but for florbetapir the broadest part of the distribution relative to the cutoff is in the abnormal range of values, whereas for CSF A β the broadest

part of the distribution is in the normal range of values, resulting in a nonlinear inverse relationship when they are plotted against each other.

Overall, we found good agreement between florbetapir and CSF A β , and we did not find any evidence that CSF A β is more likely to become abnormal prior to the accumulation of fibrillar A β early in the course of disease. Furthermore, disagreement between A β measurements was not uncommon. One in seven individuals in this study (or one in twenty after applying cutoff confidence intervals) had discordant A β markers and are therefore considered ambiguous cases according to recently revised AD diagnostic criteria³⁶. Understanding discrepancies between in vivo A β measurement is important since the new criteria treat these markers as interchangeable in terms of diagnostic utility. In addition, in vivo A β measurement to aid in development and testing of pharmaceutical treatments targeting A β is underway, making accurate measurement an essential component of subject enrichment and evaluation of drug efficacy in clinical trials. Future research may address remaining questions about the relationship between different species of A β . Forthcoming longitudinal data in the current sample will be critical for determining the clinical relevance of these imbalances.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was also supported by ADNI, Avid Radiopharmaceuticals, Inc., NIH grants P30AG010129, K01 AG030514, U01 AG024904, and the Dana Foundation.

FUNDING

This work was supported by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514.

We thank Elizabeth Mormino, Cindee Madison, Suzanne Baker, Karen Crawford, Michael Donohue, Tamie Sather, Andrew Saykin, and Michael Weiner for their contributions to data collection, analysis, and organization.

References

1. Buchhave P, Blennow K, Zetterberg H, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. *PLoS One*. 2009; 4(7):e6294. [PubMed: 19609443]
2. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. *EMBO molecular medicine*. 2009 Nov; 1(8-9):371-80. [PubMed: 20049742]
3. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. *Neurology*. 2009 Oct 13; 73(15):1193-9. [PubMed: 19822868]

4. Weigand SD, Vemuri P, Wiste HJ, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. *Alzheimers Dement*. 2011 Mar; 7(2):133–41. [PubMed: 21282074]
5. Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. *Biol Psychiatry*. 2009 Jun 1; 65(11):927–34. [PubMed: 19268916]
6. Koivunen J, Pirttila T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. *Dement Geriatr Cogn Disord*. 2008; 26(4):378–83. [PubMed: 18931497]
7. Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. *J Nucl Med*. 2009 Sep; 50(9):1464–70. [PubMed: 19690025]
8. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann Neurol*. 2010 Jan; 67(1):122–31. [PubMed: 20186853]
9. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Ann Neurol*. 2006 Mar; 59(3):512–9. [PubMed: 16372280]
10. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. *Curr Alzheimer Res*. 2010 Feb; 7(1):56–66. [PubMed: 20205671]
11. Petersen, RC. Conceptual overview. In: Petersen, RC., editor. *Mild Cognitive Impairment: Aging to Alzheimer's Disease*. New York: Oxford University Press; 2003. p. 1-14.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984 Jul; 34(7):939–44. [PubMed: 6610841]
13. Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. *Neuroimage*. 2009 May 15; 46(1):154–9. [PubMed: 19457369]
14. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. *Brain*. 2009 May; 132(Pt 5):1310–23. [PubMed: 19042931]
15. Landau SM, Mintun M, Joshi A, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Ann Neurol*. 2012;1002/ana.23650
16. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. *Clin Chem*. 2005 Feb; 51(2):336–45. [PubMed: 15563479]
17. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Ann Neurol*. 2009 Apr; 65(4):403–13. [PubMed: 19296504]
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. *Acta neuropathologica*. 2011 May; 121(5):597–609. [PubMed: 21311900]
19. Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. *J Nucl Med*. 2012 Mar; 53(3):378–84. [PubMed: 22331215]
20. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. *JAMA*. 2011 Jan 19; 305(3):275–83. [PubMed: 21245183]
21. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. *Neurology*. 2010 Jul 20; 75(3):230–8. [PubMed: 20592257]
22. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med*. 2012 Aug 30; 367(9):795–804. [PubMed: 22784036]
23. Jack CR Jr, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. *Arch Neurol*. 2011 Dec; 68(12):1526–35. [PubMed: 21825215]

24. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease. *Ann Neurol*. 1995 Oct; 38(4):643–8. [PubMed: 7574461]
25. Strozzyk D, Blennow K, White LR, Launer LJ. CSF Aβ₄₂ levels correlate with amyloid-neuropathology in a population-based autopsy study. *Neurology*. 2003 Feb 25; 60(4):652–6. [PubMed: 12601108]
26. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. *Lancet Neurol*. 2003 Oct; 2(10):605–13. [PubMed: 14505582]
27. Cairns NJ, Ikonomic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. *Arch Neurol*. 2009 Dec; 66(12):1557–62. [PubMed: 20008664]
28. Shimada H, Ataka S, Takeuchi J, et al. Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-alzheimer disease-type dementia as having AD. *J Geriatr Psychiatry Neurol*. 2011 Sep; 24(3):123–6. [PubMed: 21750305]
29. Cairns NJ, Taylor-Reinwald L, Morris JC. Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. *Alzheimers Dement*. 2010 May; 6(3):274–9. [PubMed: 20451876]
30. Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. *Acta neuropathologica*. 2012 Jul; 124(1):23–35. [PubMed: 22526019]
31. Bouwman FH, van der Flier WM, Schoonenboom NS, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. *Neurology*. 2007 Sep 4; 69(10):1006–11. [PubMed: 17785669]
32. Kok E, Haikonen S, Luoto T, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. *Ann Neurol*. 2009 Jun; 65(6):650–7. [PubMed: 19557866]
33. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. *Lancet Neurol*. 2012 Dec; 11(12):1048–56. [PubMed: 23137948]
34. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/β-amyloid₄₂ ratio as a prediction of cognitive decline in nondemented older adults. *Arch Neurol*. 2007 Mar; 64(3):343–9. [PubMed: 17210801]
35. Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement*. 2012 Jan; 8(1):65–73. [PubMed: 22047631]
36. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011 May; 7(3):263–9. [PubMed: 21514250]

Figure 1.

The inverse association between florbetapir cortical retention ratios and CSF $A\beta_{1-42}$ is shown for normal, EMCI, LMCI, and AD individuals (a). Predefined cutoffs are shown each marker (CSF $A\beta_{1-42}$ = 192 pg/mL; florbetapir = 1.11) that were derived from independent samples (see Methods). Subjects with concordant florbetapir and CSF $A\beta_{1-42}$ are in the upper left (florbetapir-/CSF $A\beta$ -) and bottom right (florbetapir+/CSF $A\beta$ +) quadrants while subjects with discordant florbetapir and CSF $A\beta_{1-42}$ are in the upper right (florbetapir+/CSF $A\beta$ -) and bottom left (florbetapir-/CSF $A\beta$ +) quadrants. A florbetapir scan for an example discordant LMCI subject (florbetapir-/CSF $A\beta$ +) is shown (b; see asterisk on scatterplot in A), indicating that the visual read is consistent with the qualitative florbetapir measurement (florbetapir cortical retention ratio = 0.98) despite abnormal CSF status. The percent of individuals from each diagnostic group in each of the 4 scatterplot quadrants is shown in the bar graph (c). The proportion of subjects who are abnormal on both markers (black bars) increases as diagnostic severity increases, but the proportions of discordant subjects (grey and striped bars) is similar across diagnostic groups and between the two types of discordance. The proportion of ApoE4 allele carriers who are concordant on both markers increases with diagnostic severity (d; black bars), the proportion of ApoE4 carriers is moderate for the two discordant groups (grey and striped bars) in the Normal and EMCI subjects.

Figure 2.

Subjects who remain discordant after applying a $\pm 5\%$ confidence interval to each cutoff.

Figure 3.

Longitudinal CSF Aβ₁₋₄₂ data is plotted against time for each subject in the longitudinal sample (a), with florbetapir+ individuals in the top row and florbetapir- subjects in the bottom row. Subjects are plotted separately by diagnosis at the time of florbetapir (left column, 27 Normal; middle column, 17 MCI; right column, 16 AD). Time of zero corresponds to the florbetapir scan, each colored line corresponds to an individual subject, and each point on the line corresponds to a CSF Aβ₁₋₄₂ value from a single LP. Dotted lines in each panel represent the CSF Aβ₁₋₄₂ cutoff value (192 pg/mL) that divides abnormal values (below line) from normal values (above line). In the top panel, CSF Aβ values that are concordant with florbetapir appear below the dotted line (both abnormal), while in the bottom panel CSF Aβ values that are concordant with florbetapir appear above the dotted line (both normal). Representative florbetapir scans are shown for three discordant subjects: (b) a CSF Aβ+/florbetapir- normal 80 yo male (florbetapir = 1.06, labeled "1" on plot); (c) a CSF Aβ-/florbetapir+ 84 yo MCI male (florbetapir cortical retention ratio = 1.12, labeled "2" on plot); and (d) a CSF Aβ+/florbetapir- 81 yo AD male (florbetapir = 0.99, labeled "3" on plot). All longitudinal CSF samples for an individual subject were included in the same immunoassay analytical run to minimize variance due to run to run and reagent lot to lot variabilities.

Table 1
Demographic and descriptive biomarker information for the cross-sectional study population.

Subject characteristics	Total cross-sectional sample		Diagnosis at florbetapir	
	Normal	Early MCI	Late MCI	AD
N	374	187	62	22
Time from LP to florbetapir (months)	0.4 (0.6)	0.4 (0.7)	0.3 (0.4)	0.3 (0.4)
Age at florbetapir (yrs)	72.7 (7.4)	71.3 (7.6)	72.5 (7.2)	74.6 (10.7)
Sex, female	45%	44%	48%	36%
Education (yrs)	16.2 (2.7)	15.8 (2.6)	16.5 (2.6)	15.9 (2.7)
MMSE at florbetapir (range: 0–30)	27.9 (2.3)	28.2 (1.6)	27.4 (2.1)	21.8 (2.8)
ADAS-cog at florbetapir (range: 0–70)	8.9 (5.1)	8 (3.7)	12.1 (4.8)	19.6 (6.3)
Abnormal biomarkers				
ApoE4 carriers	38%	39%	55%	64%
Abnormal florbetapir	46%	41%	68%	77%
Abnormal CSF Aβ₁₋₄₂	43%	36%	68%	86%
Abnormal CSF tau	31%	25%	50%	68%
Abnormal CSF p-tau_{181p}	44%	38%	68%	68%
Abnormal FDG	32%	26%	49%	100%

Table 2

Kappa (κ) statistics representing agreement in +/- status between florbetapir and the other biomarkers in the cross-sectional sample.

	Total cross-sectional sample	Diagnosis at florbetapir		
		Normal	Early MCI	Late MCI AD
CSF A β ₁₋₄₂	0.72	0.76	0.65	0.71 0.70
CSF tau	0.42	0.27	0.46	0.39 0.09
CSF p-tau _{181p}	0.52	0.45	0.52	0.48 0.32
FDG	0.26	0.21	0.11	0.33 *

* κ was invalid since all AD subjects were FDG+

Table 3

Demographic, cognitive, and biomarker profiles of discordant subjects who survived the 5% cutoff confidence interval.

Dx	Age	Sex	Edu (yrs)	ApoE4	ADAS-cog	MMSE	AVLT	HV/ICV (*10 ⁻³)	Florbeta pir	CSF Aβ ₁₋₄₂	CSF tau	CSF ptau	FDG
Florbetapir+/CSF-(N=13)	N	71	F	20	0	5	52	4.60	1.37 +	311	80	17	
		78	M	14	0	6	44	4.88	1.19 +	278	81	37	1.39
	EMCI	81	M	20	0	8	41	4.60	1.28 +	204	58	20	
		63	F	20	0	6	50	5.10	1.17 +	219	79	22	1.51
		73	F	12	1	5	46	5.87	1.40 +	211	139 +	53	1.19 (+)
		66	M	18	1	5	50	5.35	1.28 +	216	77	21	1.20 (+)
		62	F	20	1	8	55	4.40	1.19 +	230	50	22	1.39
		71	M	20	0	5	36	5.36	1.24 +	217	90	19	1.35
		68	F	14	1	7	41	4.50	1.19 +	238	85	22	1.45
		75	M	20	1	9	31	5.66	1.19 +	210		23 (+)	1.18 (+)
		82	F	14	0	7	26	5.06	1.28 +	223	111 +	26 +	1.24
		74	F	13	0	6	37	5.64	1.24 +	245	42	19	1.35
		64	M	18	1	9	34	3.36	1.23 +	218	81	24 (+)	1.11 +
Florbetapir-/CSF+ (N=7)	N	86	F	12	0	6	35	4.94	1.01	179 +	120 +	26 +	1.18 (+)
	EMCI	70	M	18	0	6	30	4.03	1.03	137 +	38	25 +	1.40
	LMCI	72	M	19	0	8	42	5.14	0.98	133 +	60	20	1.47
		67	M	17	0	11	35	5.01	0.99	162 +	140 +	31 +	1.44
		80	F	16	0	10	36	3.76	0.98	169 +	47	24 (+)	1.11 +
		91	M	20	0	13	36	3.77	0.86	179 +	38	11	1.18 (+)
	AD	76	M	16	0	26	19	4.25	0.99	180 +	146 +	27 +	1.13 +

Subjects whose PET and CSF measurements were abnormal based on previously derived cutoffs are indicated (abnormal: +, borderline: (+)); see methods

Table 4
Demographic and descriptive biomarker information for the longitudinal study population.

Subject characteristics	Diagnosis at Enrollment		
	Total longitudinal sample	Normal	MCI
N	60	29	31
Age at florbetapir (yrs)	80.1 (6.0)	82.1 (4.4)	78.3 (6.8)
Time between first and last LP (yrs)	3.1 (0.8)	3.2 (0.8)	3.1 (0.8)
Number of LP samples	3.5 (0.7)	3.5 (0.6)	3.5 (0.8)
Time between last LP and florbetapir (yrs)	1.4 (0.6)	1.4 (0.6)	1.3 (0.6)
Sex, % female	42%	48%	35%
Education (yrs)	16.0 (3.0)	16.1 (3.3)	15.9 (2.7)
ApoE4 carriers (%)	38%	52%	24%
MMSE at florbetapir (range: 0–30)	26.4 (4.2)	28.7 (1.6)	24.3 (4.7)
ADAS-cog at florbetapir (range: 0–70)	12.1 (9.2)	6.3 (3.8)	17.5 (9.5)
Abnormal biomarkers			
ApoE4 carriers	38%	24%	52%
Abnormal florbetapir	55%	41%	68%
Abnormal CSF Aβ ₁₋₄₂	62%	55%	68%
Abnormal CSF tau	32%	24%	39%
Abnormal CSF p-tau _{181p}	68%	72%	65%
Abnormal FDG	51%	31%	70%
Diagnosis at florbetapir scan			
Normal	27	24	3
MCI	17	5	12
AD	16	0	16